Vistagen Therapeutics Inc Share Price

NASDAQ: VTGN

Small Cap

$2.90

-0.35

(-10.71%)

as on September 17, 2025 at 1:29 am IST

$₹

Vistagen Therapeutics Inc Stock Performance

as on September 17, 2025 at 1:29 am IST

Day's Low
Day's High
$2.84
Day's Price Range
$3.2
$2.9
2.07%
Downside
10.34%
Upside
52 Week's Low
52 Week's High
$1.9
52-Week Price Range
$3.88
$2.9
34.48%
Downside
33.79%
Upside

Vistagen Therapeutics Inc share price movements today

Previous Close: $3.25
Open: $3.16
Volume: 1.2M
Day's Low - High: $2.84 - $3.2
52 Week Low - High: $1.9 - $3.88

Vistagen Therapeutics Inc Historical Returns

1 Month Return: -12.08 %
3 Month Return: + 22.27 %
1 Year Return: -6.13 %
3 Year Return: -49.21 %
5 Year Return: -85.36 %

Vistagen Therapeutics Inc Stock Fundamentals & Key Indicators

Check Vistagen Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$99.7M

EPS (TTM)

-1.735

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

P/B Ratio

PEG Ratio

EBITDA

-59.5M

Revenue (TTM)

646.0K

Profit Margin

0.00%

Return On Equity TTM

385885500.00%

Vistagen Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Vistagen Therapeutics Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Vistagen Therapeutics Inc	BUY	$99.7M	-85.36%	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$60.5B	252.04%	-505.15	-12.96%
Beone Medicines Ltd	NA	$39.0B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$100.3B	44.17%	27.85	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$59.6B	1.78%	14.1	31.37%

Stock Returns calculator for Vistagen Therapeutics Inc Stock including INR - Dollar returns

The Vistagen Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Vistagen Therapeutics Inc investment value today

Current value as on today

₹98,416

Returns

₹1,584

(-1.58%)

Returns from Vistagen Therapeutics Inc Stock

₹6,452 (-6.45%)

Dollar Returns*

₹4,867 (+4.87%)

Analyst Recommendation on Vistagen Therapeutics Inc Stock

Based on 10 analysts

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Vistagen Therapeutics Inc. Average target price of $14.5

Vistagen Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Vistagen Therapeutics Inc.

What analysts predicted

80%UPSIDE

Target Price

$14.5

Current Price

$2.9

Analyzed by

10 Analysts

Target

$14.50

Vistagen Therapeutics Inc target price $14.5, a slight upside of 80% compared to current price of $2.9. According to 10 analysts rating.

Vistagen Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	0	0	0	0	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0	0	0	0	0
Operating Income	-12	-6	-6	-7	-11	-12	-14	-15	-14	-15
EBITDA	-12	-6	-6	-7	-11	-11	-14	-14	-14	-14
Interest Expense	0	0	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-12	-6	-6	-6	-9	-10	-12	-14	-13	-15
Income Tax Expense	0	0	0	1,532	0	0	0	-14	-	-
Net Income	-12	-6	-6	-6	-9	-10	-12	-14	-13	-15
Net Profit Margin	-6962.98%	-3900.00%	-2369.78%	-1543.46%	-4825.85%	-12777.38%	-7082.51%	-6020.94%	90900.00%	-6186.48%

Vistagen Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Revenue	-	1	-	-	0	1	1	0	1	0
Gross Profit	-	1	-	0	0	1	1	0	1	0
Operating Income	-17	-10	-14	-24	-20	-17	-47	-59	-33	-55
EBITDA	-17	-9	-14	-24	-20	-17	-47	-58	-32	-55
Interest Expense	0	0	0	0	0	0	0	0	-	-
Depreciation	-	-	0	0	0	0	0	0	0	0
Income Before Tax	-47	-10	-14	-24	-20	-17	-47	-59	-29	-51
Income Tax Expense	0	0	0	0	0	0	0	0	0	0
Net Income	-47	-10	-14	-24	-20	-17	-47	-59	-29	-51
Net Profit Margin	0.00%	-820.44%	0.00%	0.00%	-6219.76%	-1646.09%	-4307.19%	26065.86%	-2759.59%	-10579.84%

Vistagen Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-6	-6	-6	-9	-10	-12	-14	-13	-15
Operating Cash Flow	-7	-6	-4	-7	-10	-10	-10	-10	-18
Investing Cash Flow	-	-	0	0	-5	-7	0	0	0
Financing Cash Flow	0	34	93	0	0	-	1	1	1
Change in Cash	-7	27	88	-7	-16	-18	-9	-7	-18

Vistagen Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Net Income	-10	-14	-24	-20	-17	-47	-59	-29	-51
Operating Cash Flow	-7	-9	-14	-15	-12	-45	-49	-25	-42
Investing Cash Flow	0	0	0	0	0	0	0	0	-13
Financing Cash Flow	9	16	17	4	114	10	-1	128	3
Change in Cash	2	7	2	-11	101	-34	-51	102	-52

Global Institutional Holdings in Vistagen Therapeutics Inc

Funds	Holdings
TCG Crossover Management, LLC	8.96%
StemPoint Capital LP	7.93%
Nantahala Capital Management, LLC	6.63%
Vanguard Group Inc	6.56%
COMMODORE CAPITAL LP	5.27%

See all

Insights on Vistagen Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, -15.0K → 244.0K (in $), with an average increase of 106.2% per quarter
NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 68.1% return, outperforming this stock by 74.2%
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.5% return, outperforming this stock by 165.7%
NEGATIVE IMPACT
Price Dip
In the last 7 days, VTGN stock has moved down by -18.5%
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, -13.63M → -15.09M (in $), with an average decrease of 10.7% per quarter

About Vistagen Therapeutics Inc

we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.

Organisation	Vistagen Therapeutics Inc
Headquarters	343 Allerton Avenue, South San Francisco, CA, United States, 94080
Industry	Health Technology
CEO	Mr. Shawn K. Singh J.D.
E-voting on shares	Click here to vote

Key Management of Vistagen Therapeutics Inc

Name	Title
Ms. Cynthia Lynn Anderson CPA	VP & Chief Financial Officer
Mr. Joshua S. Prince M.B.A.	Chief Operating Officer
Mr. Reid G. Adler Esq., J.D.	Chief Legal Officer
Mr. Shawn K. Singh J.D.	President, CEO & Director
Ms. Michelle Peters Wellington	Vice President of Communications
Ms. Elissa Cote	Chief Corporate Development Officer
Ms. Trisha Fitzmaurice	Senior Vice President of Human Resources
Dr. Mark J. Ginski Ph.D.	Senior VP and Head of Chemistry, Manufacturing & Controls
Mr. Mark Flather	Senior Vice President of Corporate Strategy & Capital Markets
Mr. Mark Adrian McPartland	Senior Vice President of Investor Relations

FAQs

What is Vistagen Therapeutics Inc share price today?

Vistagen Therapeutics Inc share price today is $2.9 as on September 17, 2025 at 1:29 am IST at the close of the market. Vistagen Therapeutics Inc share today touched a day high of $3.2 and a low of $2.84.

What is the 52 week high and 52 week low for Vistagen Therapeutics Inc share?

Vistagen Therapeutics Inc share touched a 52 week high of $3.88 on September 4, 2025 and a 52 week low of $1.9 on April 9, 2025. Vistagen Therapeutics Inc stock price today i.e. September 17, 2025 at 1:29 am IST is closed at $2.9,which is 25.26% down from its 52 week high and 52.63% up from its 52 week low.

What is Vistagen Therapeutics Inc's market capitalisation today?

Vistagen Therapeutics Inc market capitalisation is $0.00T as on September 17, 2025 at 1:29 am IST.

How to invest in Vistagen Therapeutics Inc Stock (VTGN) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Vistagen Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Vistagen Therapeutics Inc Shares that will get you 0.5172 shares as per Vistagen Therapeutics Inc share price of $2.9 per share as on September 17, 2025 at 1:29 am IST.

What is the minimum amount required to buy Vistagen Therapeutics Inc Stock (VTGN) from India?

Indian investors can start investing in Vistagen Therapeutics Inc (VTGN) shares with as little as ₹88.042 or $1 (as of September 17, 2025 at 3:40 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹880.42 in Vistagen Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on September 17, 2025 at 3:40 pm IST). Based on Vistagen Therapeutics Inc share’s latest price of $2.9 as on September 17, 2025 at 1:29 am IST, you will get 3.4483 shares of Vistagen Therapeutics Inc. Learn more about fractional shares .

What are the returns that Vistagen Therapeutics Inc has given to Indian investors in the last 5 years?

Vistagen Therapeutics Inc stock has given -85.36% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?